Medicine Technology 438

Gemin X Announces Publication of Preclinical Data of GX15-070 in Multiple Myeloma in Blood

MONTREAL & MALVERN, Pa.--(BUSINESS WIRE)--Mar 7, 2007 - Gemin Xannounced today that a report published in the online version ofthe journal Blood demonstrated that its lead compound, GX15-070(obatoclax), induced potent cytotoxic responses againstpatient-derived multiple myeloma tumor cells as a single-agent, andenhanced anti-myeloma effects when used as a combination therapy.GX15-070 is...

BioLineRx Presents Data on BL-1040 at Cardiovascular Revascularization Therapies Conference Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality

JERUSALEM--(BUSINESS WIRE)--Mar 7, 2007 - BioLineRx Ltd.(TASE:BLRX), Israel's leading drug development company, reportedtoday pre-clinical data from trials of BL-1040 demonstrating thatBL-1040 is effective in preventing deterioration of the myocardiumafter a myocardial infarction (MI), thereby reducing left ventricledilatation and eventual heart failure in a pig model. ProfessorJonathan Leo...

American Society of Clinical Oncology (ASCO) Accepts New Data on AVR118 for Publication in 2007 Abstract Book

YONKERS, N.Y.--(BUSINESS WIRE)--Mar 7, 2007 - Advanced ViralResearch Corp. (OTC Bulletin Board: ADVR) a bio-pharmaceuticalcompany, announced today that new information on AVR118 has beenaccepted for publication in the 2007 Proceedings of the AmericanSociety of Clinical Oncology (ASCO) Abstract publication. Thispublication will be distributed to the nearly 25,000 oncologypractioners who will...

CeNeS Pharmaceuticals plc: Update on Successful Phase III results announced on Lead Product M6G

Further analysis of Phase III trial data underlines M6G'sbenefit compared to morphine in the treatment of post-operativepain CAMBRIDGE, England, 7th March 2007 - CeNeS Pharmaceuticals plc(AIM: CEN), the Cambridge based biopharmaceutical company todayannounces additional data from the pivotal Phase III trial (M6G022)of M6G (morphine-6-glucuronide) in over 500 patients withpost-operative p...

CV Therapeutics Announces Topline MERLIN TIMI-36 Results

- Full study results will be presented at the American College ofCardiology's Scientific Session - PALO ALTO, Calif., March 06, 2007 /PRNewswire-FirstCall/ -- CVTherapeutics, Inc. announced today that an analysis of unblindeddata from the MERLIN TIMI-36 study of ranolazine shows there was noadverse trend in death or arrhythmias in patients on ranolazine.The study did not meet the primary ef...

Actelion Announces Positive Study with Bosentan (Tracleer) in CTEPH

First-Ever Placebo-controlled Study in Inoperable ChronicThromboembolic Pulmonary Hypertension - Primary Endpoint ofReduction in Pulmonary Vascular Resistance Met - Six-Minute-walkTest Unchanged - Significant Effect on Dyspnoea Score andBiological Disease Marker ALLSCHWIL, Switzerland, March 5, 2007 -Actelion Ltd (SWX:ATLN) announced today the initial results from the double-blind,pl...

British Journal of Cancer Reports Preclinical Evidence of Positive Effect of Rice Bran on Intestinal Cancer

Study Shows 51% Reduction in Intestinal Adenomas SuggestingPossible Beneficial Mediation in the Prevention of IntestinalCancer EL DORADO HILLS, Calif., March 07, 2007 /PRNewswire/ -- NutraCeaannounced today the results of a study on the effect of rice branon the number of intestinal adenomas in cancerous mice, publishedin the January 9, 2007 online edition of the prestigious BritishJournal...

Major Gene Study Uncovers Secrets of Leukemia

St. Jude Study Scans 350,000 Locations Across the Genome From 242Patients and Identifies New Mutations That Contribute to AcuteLymphoblastic Leukemia, Suggesting New Targets for Improved Therapy MEMPHIS, Tenn., March 07, 2007 /PRNewswire/ -- Investigators atSt. Jude Children's Research Hospital have discovered previouslyunsuspected mutations that contribute to the formation of pediatricacut...

La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent Lupus Phase 3 Trial

Data Support Ability of Higher Doses to Further Reduce Antibodiesto Double-Stranded DNA SAN DIEGO, March 08, 2007 /PRNewswire-FirstCall/ -- La JollaPharmaceutical Company today announced positive interim antibodyresults from its ongoing double-blind, placebo-controlledrandomized Phase 3 trial of Riquent(R) (abetimus sodium), its drugcandidate for systemic lupus erythematosus ("lupus" or "SL...

Hollis-Eden Announces Cancellation of Acute Radiation Syndrome RFP by Department of Health and Human Services

SAN DIEGO--(BUSINESS WIRE)--Mar 8, 2007 - Hollis-EdenPharmaceuticals, Inc. (NASDAQ:HEPH) today announced that it wasinformed late Wednesday, March 07, 2007, by the Department ofHealth & Human Services (HHS) that NEUMUNE(R), the Company'sproduct candidate for the treatment of Acute Radiation Syndrome(ARS) was found technically unacceptable and was no longer in thecompetitive range for th...

[previous] [next]